 |
|
Perspectives on Verteporfin Therapy Combined With Intravitreal Corticosteroids
Arch Ophthalmol. 2006;124:561-563.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
Since its approval in 1999, photodynamic therapy (PDT) using verteporfin has become the most important strategy in the treatment of neovascular age-related macular degeneration (AMD). Verteporfin therapy has a proven benefit seen in many subtypes of choroidal neovascularization (CNV). In predominantly classic lesions, 59% of verteporfin-treated patients lost fewer than 3 lines as compared with 31% of sham-treated eyes.1 In patients with occult CNV with smaller lesions or lower levels of visual acuity, stable vision is seen in 51% of eyes in the verteporfin group while only 25% of sham-treated eyes maintained stable vision.2 Subgroup analysis suggests that verteporfin may also reduce the risk of vision loss in lesions with minimally classic features smaller than 4 Macular Photocoagulation Study disc areas. Most importantly, vision stabilization and absence of leakage activity was maintained during an extended follow-up of as long as 5 years with no relevant need for retreatment beyond 18 . . . [Full Text of this Article]
AUTHOR INFORMATION
Ursula Schmidt-Erfurth, MD;
Stephan Michels, MD;
Albert Augustin, MD
Author Affiliations: Department of Ophthalmology, University of Vienna, Vienna, Austria (Drs Schmidt-Erfurth and Michels); and Department of Ophthalmology, Städt Klinikum, Karlsruhe, Germany (Dr Augustin).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
Should Corticosteroids Be Considered as Part of the Standard Care With Photodynamic Therapy?
Marco Zarbin
Arch Ophthalmol. 2006;124(4):563-571.
EXTRACT
| FULL TEXT
|
